Thermolabile 5,10-methylenetetrahydrofolate Reductase As a Cause of Mild Hyperhomocysteinemia

Overview

Journal Am J Hum Genet

Publisher Cell Press

Specialty Genetics

Date 1995 Jan 1

PMID 7825569

Citations 56

Authors

A M Engbersen

D G Franken

G H Boers

E M STEVENS

F J Trijbels

H J Blom

Affiliations

Soon will be listed here.

Abstract

Thermolability of 5,10-methylenetetrahydrofolate reductase (MTHFR) was examined as a possible cause of mild hyperhomocysteinemia in patients with premature vascular disease. Control subjects and vascular patients with mild hyperhomocysteinemia and with normohomocysteinemia were studied. The mean (+/- SD) specific MTHFR activity in lymphocytes of 22 control subjects was 15.6 (+/- 4.7) nmol CH2O/mg protein/h (range: 9.1-26.6), and the residual activity (+/- SD) after heat inactivation for 5 min at 46 degrees C was 55.3 (+/- 12.0)% (range: 35.9-78.3). By measurement of MTHFR activity, two distinct subgroups of hyperhomocysteinemic patients became evident. One group (n = 11) had thermolabile MTHFR with a mean (+/- SD) specific activity of 8.7 (+/- 2.1) nmol CH2O/mg protein/h (range: 5.5-12.7) and a residual activity, after heat inactivation, ranging from 0% to 33%. The other group (n = 28) had normal specific activity (+/- SD) of 21.5 (+/- 7.2) nmol CH2O/mg protein/h (range: 10.0-39.0) and a normal residual activity (+/- SD) of 53.8 (+/- 9.2)% (range: 33.1-71.5) after heat inactivation. The mean (+/- SD) specific activity of 29 normohomocysteinemic patients was 20.7 (+/- 6.5) nmol CH2O/mg protein/h (range: 9.4-33.8), and the mean (+/- SD) residual activity after heat inactivation was 58.2 (+/- 10.2)% (range: 43.0-82.0). Thus, in 28% of the hyperhomocysteinemic patients with premature vascular disease, abnormal homocysteine metabolism could be attributed to thermolabile MTHFR.

Citing Articles

MTHFR C677T rs1801133 and TP53 Pro72Arg rs1042522 gene variants in South African Indian and Caucasian psoriatic arthritis patients.

Naidoo P, Maharaj A, Ghazi T, Chuturgoon A Genet Mol Biol. 2025; 48(1):e20230325.

PMID: 39792433 PMC: 11721215. DOI: 10.1590/1678-4685-GMB-2023-0325.

Single nucleotide polymorphism of rs1801133 associated with elevated Hcy levels affects susceptibility to cerebral small vessel disease.

Yuan H, Fu M, Yang X, Huang K, Ren X PeerJ. 2020; 8:e8627.

PMID: 32117640 PMC: 7036271. DOI: 10.7717/peerj.8627.

The frequency of Raynaud’s phenomenon in patients with methylenetetrahydrofolate reductase gene mutation and hyperhomocysteinemia.

Yalcin K, Kosar A Turk J Med Sci. 2019; 49(5):1444-1449.

PMID: 31651110 PMC: 7018243. DOI: 10.3906/sag-1903-206.

Ethnogeographic prevalence and implications of the 677C>T and 1298A>C polymorphisms in US primary care populations.

Graydon J, Claudio K, Baker S, Kocherla M, Ferreira M, Roche-Lima A Biomark Med. 2019; 13(8):649-661.

PMID: 31157538 PMC: 6630484. DOI: 10.2217/bmm-2018-0392.

C677T Gene Polymorphism as Risk Factor for Psoriasis in Saudis.

Huraib G, Al Harthi F, Arfin M, Khlaiwi A, Rizvi S, Al-Asmari A Biomark Insights. 2019; 14:1177271919830973.

PMID: 30828245 PMC: 6390219. DOI: 10.1177/1177271919830973.

References

Wendel U, Claussen U, Diekmann E . Prenatal diagnosis for methylenetetrahydrofolate reductase deficiency. J Pediatr. 1983; 102(6):938-40. DOI: 10.1016/s0022-3476(83)80029-8. View

Kang S, Zhou J, Wong P, Kowalisyn J, Strokosch G . Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet. 1988; 43(4):414-21. PMC: 1715503. View

Wada Y, Narisawa K, Arakawa T . Infantile type of homocystinuria with 5,10-methylenetetrahydrofolate reductase deficiency. Monogr Hum Genet. 1978; 9:140-6. DOI: 10.1159/000401626. View

Kang S, Wong P, Bock H, Horwitz A, Grix A . Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutations. Am J Hum Genet. 1991; 48(3):546-51. PMC: 1682989. View

Franken D, Boers G, Blom H, Trijbels F, KLOPPENBORG P . Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb. 1994; 14(3):465-70. DOI: 10.1161/01.atv.14.3.465. View

Rosenblatt D, Erbe R . Methylenetetrahydrofolate reductase in cultured human cells. II. Genetic and biochemical studies of methylenetetrahydrofolate reductase deficiency. Pediatr Res. 1977; 11(11):1141-3. DOI: 10.1203/00006450-197711000-00005. View

Benevenga N . Betaine in the treatment of homocystinuria. N Engl J Med. 1984; 310(4):265-6. DOI: 10.1056/NEJM198401263100421. View

Kang S, Wong P, Zhou J, Sora J, Lessick M, Ruggie N . Thermolabile methylenetetrahydrofolate reductase in patients with coronary artery disease. Metabolism. 1988; 37(7):611-3. DOI: 10.1016/0026-0495(88)90076-5. View

Ruyter I . Release of formaldehyde from denture base polymers. Acta Odontol Scand. 1980; 38(1):17-27. DOI: 10.3109/00016358008997715. View

10.

Mudd S, Havlik R, Levy H, MCKUSICK V, Feinleib M . A study of cardiovascular risk in heterozygotes for homocystinuria. Am J Hum Genet. 1981; 33(6):883-93. PMC: 1685155. View

11.

Hyland K, Smith I, Bottiglieri T, Perry J, Wendel U, Clayton P . Demyelination and decreased S-adenosylmethionine in 5,10-methylenetetrahydrofolate reductase deficiency. Neurology. 1988; 38(3):459-62. DOI: 10.1212/wnl.38.3.459. View

12.

Kang S, Wong P, MALINOW M . Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr. 1992; 12:279-98. DOI: 10.1146/annurev.nu.12.070192.001431. View

13.

Kang S, Wong P, SUSMANO A, Sora J, Norusis M, Ruggie N . Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet. 1991; 48(3):536-45. PMC: 1682970. View

14.

Boers G, Fowler B, Smals A, Trijbels F, Leermakers A, Kleijer W . Improved identification of heterozygotes for homocystinuria due to cystathionine synthase deficiency by the combination of methionine loading and enzyme determination in cultured fibroblasts. Hum Genet. 1985; 69(2):164-9. DOI: 10.1007/BF00293290. View

15.

Boers G, Smals A, Trijbels F, Fowler B, BAKKEREN J, Schoonderwaldt H . Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med. 1985; 313(12):709-15. DOI: 10.1056/NEJM198509193131201. View

16.

Jondal M, Holm G, Wigzell H . Surface markers on human T and B lymphocytes. I. A large population of lymphocytes forming nonimmune rosettes with sheep red blood cells. J Exp Med. 1972; 136(2):207-15. PMC: 2139198. DOI: 10.1084/jem.136.2.207. View

17.

Finkelstein J . Methionine metabolism in mammals. J Nutr Biochem. 1990; 1(5):228-37. DOI: 10.1016/0955-2863(90)90070-2. View

18.

Fowler B, Kraus J, Packman S, ROSENBERG L . Homocystinuria. Evidence for three distinct classes of cystathionine beta-synthase mutants in cultured fibroblasts. J Clin Invest. 1978; 61(3):645-53. PMC: 372577. DOI: 10.1172/JCI108976. View

19.

LOWRY O, ROSEBROUGH N, FARR A, RANDALL R . Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193(1):265-75. View

20.

Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B . Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991; 324(17):1149-55. DOI: 10.1056/NEJM199104253241701. View